Essec\Faculty\Model\Contribution {#2190
#_index: "academ_contributions"
#_id: "2201"
#_source: array:26 [
"id" => "2201"
"slug" => "patient-characteristics-and-treatment-of-neovascular-age-related-macular-degeneration-in-france-the-lueur-1-observational-study"
"yearMonth" => "2011-04"
"year" => "2011"
"title" => "Patient Characteristics and Treatment of Neovascular Age-related Macular Degeneration in France: The LUEUR 1 Observational Study"
"description" => "COHEN, S.Y., SOUIED, E.H., WEBER, A.P., DUPEYRON, G., PUYOU DE POUVOURVILLE, G. et LIEVRE, M. (2011). Patient Characteristics and Treatment of Neovascular Age-related Macular Degeneration in France: The LUEUR 1 Observational Study. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i>, 249(4), pp. 521-527."
"authors" => array:6 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "puyou-de-pouvourville-gerard"
]
1 => array:1 [
"name" => "COHEN S.-Y."
]
2 => array:1 [
"name" => "SOUIED E.H."
]
3 => array:1 [
"name" => "WEBER André Paul"
]
4 => array:1 [
"name" => "DUPEYRON G."
]
5 => array:1 [
"name" => "LIEVRE M."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-02-02 16:16:18"
"publicationUrl" => "https://www.researchgate.net/publication/47701649_Patient_characteristics_and_treatment_of_neovascular_age-related_macular_degeneration_in_France_The_LUEUR1_observational_study"
"publicationInfo" => array:3 [
"pages" => "521-527"
"volume" => "249"
"number" => "4"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Age-related macular degeneration is the primary cause of blindness in developed countries. Current treatments of this degenerative disease mainly include laser, photodynamic therapy with verteporfin and administration of anti-vascular endothelial growth factors. The LUEUR (LUcentis® En Utilisation Réelle) study is composed of a cross-sectional part (LUEUR1), which examined the current management of wet AMD in France, and a follow-up part (LUEUR2), which will assess the development of patients treated for wet AMD over 4 years. Here we describe the results of LUEUR1. Patients with wet AMD were enrolled during a routine medical examination in LUEUR1, a cross-sectional, observational, prospective, multicentre study. Investigators recorded patient demographics, visual acuity, characteristics of wet AMD lesions, date of AMD diagnosis, comorbidities, previous treatments, treatments prescribed at inclusion, and low vision rehabilitation. A total of 72 investigators recruited 1,019 patients with wet AMD, corresponding to 1,405 eyes affected by the disease. The mean age of patients was 78.7 ± 7.3 years. Most were female (62.3%) and non-smokers (66.9%). The mean visual acuity was 49.12 ± 24.18 Early Treatment Diabetic Retinopathy Study letters. Most eyes showed occult (52.8%) and subfoveal (84.6%) choroidal neovascularisation. Bilateral wet AMD affected 37.9% of patients. The median time since diagnosis was 12 months. Ranibizumab-based therapy (67.3%) and photodynamic therapy (29.8%) were the most frequent previous treatments. Prior to inclusion, 5.6% of patients had low vision rehabilitation. When a treatment was prescribed on the day of inclusion, it was most often ranibizumab (89.0% of all treatments at inclusion). The results of this study illustrate the impact of anti-vascular endothelial growth factor therapies on the treatment of wet AMD in a real-life context. Specifically, ranibizumab-based therapy appears to have largely replaced laser photocoagulation and verteporfin-based photodynamic therapy."
"en" => "Age-related macular degeneration is the primary cause of blindness in developed countries. Current treatments of this degenerative disease mainly include laser, photodynamic therapy with verteporfin and administration of anti-vascular endothelial growth factors. The LUEUR (LUcentis® En Utilisation Réelle) study is composed of a cross-sectional part (LUEUR1), which examined the current management of wet AMD in France, and a follow-up part (LUEUR2), which will assess the development of patients treated for wet AMD over 4 years. Here we describe the results of LUEUR1. Patients with wet AMD were enrolled during a routine medical examination in LUEUR1, a cross-sectional, observational, prospective, multicentre study. Investigators recorded patient demographics, visual acuity, characteristics of wet AMD lesions, date of AMD diagnosis, comorbidities, previous treatments, treatments prescribed at inclusion, and low vision rehabilitation. A total of 72 investigators recruited 1,019 patients with wet AMD, corresponding to 1,405 eyes affected by the disease. The mean age of patients was 78.7 ± 7.3 years. Most were female (62.3%) and non-smokers (66.9%). The mean visual acuity was 49.12 ± 24.18 Early Treatment Diabetic Retinopathy Study letters. Most eyes showed occult (52.8%) and subfoveal (84.6%) choroidal neovascularisation. Bilateral wet AMD affected 37.9% of patients. The median time since diagnosis was 12 months. Ranibizumab-based therapy (67.3%) and photodynamic therapy (29.8%) were the most frequent previous treatments. Prior to inclusion, 5.6% of patients had low vision rehabilitation. When a treatment was prescribed on the day of inclusion, it was most often ranibizumab (89.0% of all treatments at inclusion). The results of this study illustrate the impact of anti-vascular endothelial growth factor therapies on the treatment of wet AMD in a real-life context. Specifically, ranibizumab-based therapy appears to have largely replaced laser photocoagulation and verteporfin-based photodynamic therapy."
]
"authors_fields" => array:2 [
"fr" => "Economie"
"en" => "Economics"
]
"indexedAt" => "2024-04-16T05:22:01.000Z"
"docTitle" => "Patient Characteristics and Treatment of Neovascular Age-related Macular Degeneration in France: The LUEUR 1 Observational Study"
"docSurtitle" => "Journal articles"
"authorNames" => "<a href="/cv/puyou-de-pouvourville-gerard">PUYOU DE POUVOURVILLE Gérard</a>, COHEN S.-Y., SOUIED E.H., WEBER André Paul, DUPEYRON G., LIEVRE M."
"docDescription" => "<span class="document-property-authors">PUYOU DE POUVOURVILLE Gérard, COHEN S.-Y., SOUIED E.H., WEBER André Paul, DUPEYRON G., LIEVRE M.</span><br><span class="document-property-authors_fields">Economics</span> | <span class="document-property-year">2011</span>"
"keywordList" => ""
"docPreview" => "<b>Patient Characteristics and Treatment of Neovascular Age-related Macular Degeneration in France: The LUEUR 1 Observational Study</b><br><span>2011-04 | Journal articles </span>"
"docType" => "research"
"publicationLink" => "<a href="https://www.researchgate.net/publication/47701649_Patient_characteristics_and_treatment_of_neovascular_age-related_macular_degeneration_in_France_The_LUEUR1_observational_study" target="_blank">Patient Characteristics and Treatment of Neovascular Age-related Macular Degeneration in France: The LUEUR 1 Observational Study</a>"
]
+lang: "en"
+"_type": "_doc"
+"_score": 8.903453
+"parent": null
}
